Genomic Health, Inc.
301 Penobscot Drive
About Genomic Health, Inc.About Genomic Health Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today. The company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient's journey, from diagnosis to treatment selection and monitoring. The company is based in Redwood City, California, with European headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com and follow the company on Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn.
About Oncotype DX® The Oncotype DX® portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. With half a million patients tested in more than 80 countries, the Oncotype DX tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment. To learn more about Oncotype DX tests, visit www.OncotypeDX.com, www.mybreastcancertreatment.org and www.myprostatecancertreatment.org.
404 articles about Genomic Health, Inc.
Exact Sciences Completes Combination with Genomic Health, Creating Leading Global Cancer Diagnostics Company
Combined company joins two leading brands in cancer diagnostics, Cologuard® and Oncotype DX®, providing a strong platform for continued growth
New TAILORx Data, Published Today in JAMA Oncology, Add to Strong Evidence Base Reinforcing Unique Ability of Oncotype DX Breast Recurrence Score® Test to Guide Chemotherapy Treatment
Clinical Outcomes in Patients with High Recurrence Score® Results Presented Today in Oral Session at ESMO 2019 Congress
Genomic Health Reports 19% Revenue Growth and Record Profit in Second Quarter 2019, Raises Full-Year Guidance
Genomic Health, Inc. reported financial results and business progress for the quarter ended June 30, 2019.
Genomic (GHDX) Alert: Johnson Fistel Investigates Proposed Sale of Genomic Health, Inc.; Are Shareholders Getting a Fair Deal?
Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Genomic Health, Inc. breached their fiduciary duties in connection with the proposed sale of the Company to Exact Sciences Corp..
Exact Sciences and Genomic Health to Combine, Creating Leading Global Cancer Diagnostics Company
Exact Sciences Corp. and Genomic Health, Inc. announced that the companies have entered into a definitive agreement under which Exact Sciences will combine with Genomic Health for $72.00 per share in a cash and stock transaction valued at $2.8 billion.
The combined companies will have revenue drivers of two commercially available diagnostics tools, Cologuard and Oncotype DX.
Genomic Health to Announce Second Quarter 2019 Financial Results and Host Conference Call on Thursday, August 1, 2019
Genomic Health, Inc. (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Thursday, August 1 at 4:30 p.m. Eastern Time to discuss its second quarter 2019 financial results
German Federal Joint Committee (G-BA) Issues Exclusive Nationwide Reimbursement Decision for Oncotype DX Breast Recurrence Score® Test
Reimbursement Decision Follows IQWiG's Recommendation Based on TAILORx Study Results
Secondary Analysis of Landmark TAILORx Results, Published Today in The New England Journal of Medicine, Affirms Unique Ability of Oncotype DX Breast Recurrence Score® to Predict Chemotherapy Benefit
Additional Detail in Patients Age 50 or Younger Presented Today in Oral Session at 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
Updated ASCO Guidelines Establish TAILORx-defined Cutoffs for Determining Chemotherapy Benefit with the Oncotype DX Breast Recurrence Score® Test in Node-negative Breast Cancer
Genomic Health, Inc. announced that its Oncotype DX Breast Recurrence Score® test and the TAILORx results have been recommended to guide chemotherapy treatment use in patients with node-negative early-stage breast cancer by the American Society of Clinical Oncology in its 2019 Guidelines for Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy.
Genomic Health to Present at the Jefferies 2019 Healthcare Conference
Genomic Health, Inc. announced that management will present at the Jefferies 2019 Healthcare Conference in New York City on Wednesday, June 5, 2019 at 2 p.m. Eastern Time.
Genomic Health Reports First Quarter 2019 Financial Results and Recent Business Progress
Genomic Health, Inc. reported financial results and business progress for the quarter ended March 31, 2019.
Genomic Health to Announce First Quarter 2019 Financial Results and Host Conference Call on Tuesday, May 7, 2019
Genomic Health, Inc. announced that the company will host a conference call and webcast on Tuesday, May 7 at 4:30 p.m. Eastern Time to discuss its first quarter 2019 financial results.
New Long-term Outcomes Data Presented at St. Gallen International Breast Cancer Conference Reinforce TAILORx Treatment Paradigm and Standard of Care Use for Oncotype DX Breast Recurrence Score® Test
Importance of tailoring chemotherapy use and differences between tests acknowledged by leading international breast cancer specialists
Genomic Health Reports Record 2018 Fourth Quarter and Year-end Financial Results and Provides 2019 Financial Guidance
Guides to 14% Revenue Growth and 50% Non-GAAP Net Income Growth at High End of 2019 Outlook
Genomic Health to Announce Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call on Wednesday, February 20, 2019
Genomic Health, Inc. announced that the company will host a conference call and webcast on Wednesday, February 20 at 4:30 p.m. Eastern Time to discuss its fourth quarter and year-end 2018 financial results.
Oncotype DX® Genomic Prostate Score® Established as First Genomic Test with Prospective Validation for Predicting Adverse Pathology in Newly Diagnosed Patients
Genomic Health, Inc. (Nasdaq: GHDX) today announced the publication of results from a multi-center, prospective validation study of the Oncotype DX® Genomic Prostate Score® (GPS™) test in newly diagnosed men with clinically low-risk prostate cancer who elected immediate radical prostatectomy after receiving the test.
Genomic Health Marks More than 1 Million Patients Worldwide Who Have Benefited from Oncotype DX Testing in Personalizing Cancer Treatment Decisions to Improve Outcomes
Pioneering Precision Medicine While Saving Healthcare Costs
NICE Expands Recommendation for the Oncotype DX Breast Recurrence Score® Test to More Patients with Early-Stage Breast Cancer Within the United Kingdom
Only test recommended based on its ability to predict chemotherapy benefit
Genomic Health to Present at the 37th Annual J.P. Morgan Healthcare Conference
Genomic Health, Inc. (NASDAQ: GHDX) today announced that Kim Popovits, chairman of the board, chief executive officer and president, will present at the 37th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Monday, January 7, 2019 at 11:30 a.m. Pacific Time.